Markella V Zanni MD
Diabetes, Lipid Metabolism
Instructor in Medicine, Massachusetts General Hospital
Join to View Full Profile
0 Emerson PlSuite 112Boston, MA 02114
Phone+1 617-726-6813
Fax+1 617-726-1241
Join Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Markella Zanni, MD is an endocrinologist in Boston, Massachusetts. She is currently licensed to practice medicine in Massachusetts. She is an Instructor in Medicine at Massachusetts General Hospital.
Education & Training
Mass General Brigham/Massachusetts General HospitalFellowship, Endocrinology, Diabetes, and Metabolism, 2007 - 2010
Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 2004 - 2007
Harvard Medical SchoolClass of 2004
Certifications & Licensure
MA State Medical License 2007 - 2026
American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
Publications & Presentations
PubMed
- Pitavastatin, Procollagen Pathways, and Plaque Stabilization in Patients With HIV: A Secondary Analysis of the REPRIEVE Randomized Clinical Trial.Márton Kolossváry, Samuel R Schnittman, Markella V Zanni, Kathleen V Fitch, Carl J Fichtenbaum
JAMA Cardiology. 2025-03-01 - 1 citationsPitavastatin Is Well-Tolerated With no Detrimental Effects on Physical Function.Kristine M Erlandson, Triin Umbleja, Heather J Ribaudo, Jennifer A Schrack, Edgar T Overton
Clinical Infectious Diseases. 2025-02-24 - 1 citationsMeal replacement therapy for obesity and diabetes remission: efficacy assessment and considerations of barriers and facilitators to adherence among U.S. individuals wi...Claudia G Durbin, Ainsley Hutchison, Talia Colecchi, Jennifer Mulligan, Sreevidya Bodepudi
Reviews in Endocrine & Metabolic Disorders. 2025-02-01
Press Mentions
Study Highlights Gaps in CVD Risk Models for People with HIVJanuary 19th, 2025- Gulati: ASPC Summit to Explore ‘Protecting the Heart of One and All’July 22nd, 2021
REPRIEVE MR: Characterizing Cardiac Dysfunction in HIV and Testing the Effect of StatinsJuly 1st, 2017- Join now to see all
Grant Support
- Effects of SGLT2 Inhibition on Coronary Flow Reserve and Other Key Indices Relevant to Type 2 Myocardial Infarction Risk among Women with HIVMASSACHUSETTS GENERAL HOSPITAL2024–2029
- Myocardial Fibrosis and Steatosis Burden and Region-Specific Predictors of Progression among ART-treated Women with HIV infection in sub-Saharan Africa (The MUTIMA Study)UNIVERSITY OF WASHINGTON2023–2027
- Consequences of Persistent Immune Activation among ART-treated Women with HIVMASSACHUSETTS GENERAL HOSPITAL2021–2026
- Arterial Inflammation and Coronary Microvascular Dysfunction among Women with HIV: Missing Pieces to the MI Risk PuzzleMASSACHUSETTS GENERAL HOSPITAL2019–2025
